Table 3.
Parameter estimates from population pharmacokinetic analysis and bootstrap analysis of oseltamivir and oseltamivir carboxylate
| Parameter | Final model | Bootstrap(n = 500) | ||
|---|---|---|---|---|
| Estimate | %RSE | Median | 2.5–97.5 percentile | |
| ka | 0.6 | 8.3 | 0.65 | 0.56–1.09 |
| CL/F OS | 532 | 4.9 | 546 | 492–600 |
| CL/F OC | 20 | 4.9 | 20 | 18–23 |
| Vd/F OS | 289 | 17.6 | 346 | 224–697 |
| Vd/F OC | 152 | 5.6 | 155 | 137–172 |
| PG effect on CL/F OC | 8.1 | 25.9 | 8.3 | 4.2–12.9 |
| PG effect on Vd /F OC | 56 | 28.8 | 68 | 27–114 |
| Inter-individual variability (%CV) | ||||
| ka | 38.1 | 15.4 | 30.3 | 0.3–60 |
| CL/F OS | 39.2 | 10.4 | 34.1 | 25–43 |
| CL/F OC | 30.8 | 4.8 | 30.8 | 26–36 |
| V/F OS | 92.7 | 27.1 | 78.0 | 30–110 |
| V/F OC | 35.9 | 14.0 | 31.1 | 23–45 |
| Residual variability | ||||
| Proportional error for OS | 50.3 %CV | 6.6 | 46.3 %CV | 42–51 %CV |
| Additive error for OS | 1.5 ng ml–1 (LOQ 2 ng ml–1) | 58.4 | 1.6 ng ml–1 | 1.1–5.2 ng ml–1 |
| Proportional error for OC | 15 %CV | Fixed | 5 %CV | Fixed |
| Additive error for OC | 35.7 ng ml–1 (LOQ 10 ng ml–1) | 0.1 | 34.9 ng ml–1 | 28–41 ng ml–1 |